141613-46-9

Upstream product

• 186581-53-3 diazomethane 
• 6948-30-7 5-bromoveratralaldehyde 
• 917-64-6 methyl magnesium iodide 
• 781654-31-7 3-bromo-4,5-dimethoxybenzonitrile 
• 70574-46-8 3-bromo-4,5-dimethoxybenzoyl chloride 
• 506-82-1 dimethylcadmium 
• 5293-21-0 1-(3-bromo-4,5-dimethoxyphenyl)-1-ethanol 
• 103653-14-1 3-bromo-4-hydroxy-5-methoxyacetophenone 
• 77-78-1 dimethyl sulfate 
• 20731-48-0 3-bromo-4,5-dimethoxybenzoic acid 

Downstream Products

• 141613-47-0 ethyl 3-(3-bromo-4,5-dimethoxyphenyl)-3-oxopropionate 
• 134611-50-0 5-acetyl-2,3-dimethoxybenzonitrile 
• 1198078-68-0 C₁₇H₁₆BrNO₅S 
• 1198078-98-6 C₂₂H₂₆BrNO₅S 
• 1198078-97-5 C₂₂H₂₆BrNO₆ 
• 1198078-96-4 C₂₂H₂₆BrNO₆ 
• 141613-40-3 7-<2-(2-aminothazol-4-yl)-2-<(Z)-(1-carboxy-1-methylethoxy)imino>acetamido>-3-<3-(3-bromo-4,5-dihydroxyphenyl)-2-(ethoxycarbonyl)-3-oxopropyl>ceph-3-em-4-carboxylic acid 
• 141613-35-6 7-amino-3-<2-(ethoxycarbonyl)-3-(3-bromo-4,5-dihydroxyphenyl)-3-oxopropyl>ceph-3-em-4-carboxylic acid 
• 141613-48-1 ethyl 3-(3-bromo-4,5-dihydroxyphenyl)-3-oxopropionate 

Relevant academic research and scientific papers

Lithiation of 2-aryl-2-methyl-1,3-dioxolanes with PMDTA-complexed butyllithium

The metalation of chloro- and methoxy-substituted acetophenone ketals with butyllithium (BuLi) and with N,N,N',N″,N″-pentamethyldiethylenetriamine-complexed butyllithium (BuLi/PMDTA) has been investigated. The lithio species thus generated were carboxylat

Discovery of a long-acting, peripherally selective inhibitor of catechol- O -methyltransferase

Novel nitrocatechol-substituted heterocycles were designed and evaluated for their ability to inhibit catechol-O-methyltransferase (COMT). Replacement of the pyrazole core of the initial hit 4 with a 1,2,4-oxadiazole ring resulted in a series of compounds endowed with longer duration of COMT inhibition. Incorporation of a pyridine N-oxide residue at position 3 of the 1,2,4-oxadiazole ring led to analogue 37f, which was found to possess activity comparable to entacapone and lower toxicity in comparison to tolcapone. Lead structure 37f was systematically modified in order to improve selectivity and duration of COMT inhibition as well as to minimize toxicity. Oxadiazole 37d (2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4, 6-dimethylpyridine 1-oxide (BIA 9-1067)) was identified as a long-acting, purely peripheral inhibitor, which is currently under clinical evaluation as an adjunct to l-Dopa therapy of Parkinson's disease.

NOVEL MODULATORS OF PROTEIN KINASE SIGNALING

The present invention provides new tyrphostin derivatives acting as protein kinase (PK) and receptor kinase (RK) signaling modulators. The invention further provides methods of their preparation, pharmaceutical compositions including such compounds, and m

Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues

Cephalosporins with new catechol substituents at C-3' have been synthesized, including novel compounds with C-3' carbon-carbon bonds. Many of these compounds have high potency against Gram-negative bacteria, in particular against resistant strains like Ps